Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | HPGD | P15428 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.45 |
| ▸ | CTSL | P07711 | 4/20 | 0.45 |
| ▸ | CTSS | P25774 | 3/20 | 0.45 |
| ▸ | CTSK | P43235 | 3/20 | 0.45 |
| ▸ | CTSB | P07858 | 3/20 | 0.45 |
| ▸ | CTSV | O60911 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.43 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6061993 | 0.89 | MAPT (0.49) | RAB9AALDH1A1SMN1; SMN2CTSLCTSS | |
| SCHEMBL6061910 | 0.85 | CTSL (0.56) | CTSLCTSSCTSKCTSBCTSV | |
| SCHEMBL6739753 | 0.85 | CTSB (0.62) | RAB9ACTSLCTSSCTSKCTSB | |
| SCHEMBL6737511 | 0.84 | CTSL (0.62) | CTSLCTSSCTSKCTSBCTSV | |
| SCHEMBL6744442 | 0.84 | CTSL (0.50) | CTSLCTSSCTSKCTSBCTSV | |
| SCHEMBL5529184 | 0.82 | RAB9A (0.50) | RAB9AALDH1A1HPGDSMN1; SMN2ATM | |
| SCHEMBL6737541 | 0.82 | CTSL (0.43) | ALDH1A1HPGDCTSLCTSSCTSK | |
| SCHEMBL6742227 | 0.82 | CTSS (0.61) | CTSLCTSSCTSKCTSBCTSV | |
| SCHEMBL6742222 | 0.82 | CTSS (0.61) | CTSLCTSSCTSKCTSBCTSV | |
| SCHEMBL6744103 | 0.81 | CTSL (0.53) | RAB9AALDH1A1CTSLCTSSCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040014796-A1 | Novel compounds and compositions as cathepsin S inhititors | AXYS PHARMACEUTICALS, INC. | 2004-01-22 | — | — | US | disclosed |
| US-6492362-B1 | Compounds and compositions as cathepsin S inhibitors | AXYS PHARMACEUTICALS, INC. | 2002-12-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040014796-A1 | Novel compounds and compositions as cathepsin S inhititors | CTSS, CTSB, CTSE | RAB9A 401/4885ALDH1A1 4044/4885HPGD 1593/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.